Fmoc-OSu

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-OSu
• 英文别名: 1-((9H-fluoren-9-yl)methoxy)pyrrolidine-2,5-dione；1-(9H-fluoren-9-ylmethoxy)pyrrolidine-2,5-dione
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: QLLQYWNKFWFWTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N^α-<2-(Benzylthio)ethyl>glycine 、 Fmoc-OSu 以 水 、 乙腈 为溶剂， 反应 4.0h， 以42%的产率得到2-[2-benzylsulfanylethyl(9H-fluoren-9-ylmethoxycarbonyl)amino]acetic acid
  参考文献：
  名称：

  Building units for N-backbone cyclic peptides. Part 4.1 Synthesis of protected Nα-functionalized alkyl amino acids by reductive alkylation of natural amino acids

  摘要：

  报道了一种通过天然氨基酸的还原烷基化合成保护的Nα-(γ-Y-烷基)氨基酸(Y为硫、氨基或羧基基团)及相关化合物的新方法。这些新型氨基酸作为合成骨架环肽的构建单元，在α-氨基位置通过叔丁氧羰基(Boc)或9-芴甲氧羰基(Fmoc)进行正交保护，并使用三甲基硅烷临时保护，以便通过固相肽合成法将其并入肽链中。

  DOI：

  10.1039/a608389g

文献信息

• [EN] UREA DERIVATIVES OF AMPHOTERICIN B DERIVED FROM SECONDARY AMINES<br/>[FR] DÉRIVÉS D'URÉE DE L'AMPHOTÉRICINE B DÉRIVÉE D'AMINES SECONDAIRES
  申请人：UNIV ILLINOIS

  公开号：WO2016112243A1

  公开（公告）日：2016-07-14

  Provided are certain urea derivatives of amphotericin B (AmB) having improved therapeutic index compared to AmB. The compounds of the invention are less toxic than AmB and are useful to treat fungal infections. In certain embodiments the urea derivative of AmB is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof: wherein, independently for each occurrence: R represents methyl, ethyl, propyl, or isopropyl; R' represents methyl, ethyl, propyl, or isopropyl; or R and R', taken together with the nitrogen atom to which they are attached, represent a radical of a cyclic secondary amine. Also provided are methods for making the urea derivatives of AmB.

  提供了与两性霉素B（AmB）相比具有改善的治疗指数的某些尿素衍生物。本发明的化合物比AmB毒性更小，并且可用于治疗真菌感染。在某些实施例中，AmB的尿素衍生物是由以下式（I）表示的化合物或其药用可接受的盐：其中，对于每次出现独立地：R代表甲基、乙基、丙基或异丙基；R'代表甲基、乙基、丙基或异丙基；或R和R'与它们连接的氮原子一起表示环状二级胺的基团。还提供了制备AmB的尿素衍生物的方法。
• An expedient synthesis of Nα-protected-l-tetrahydrofuranylglycine and its application in the synthesis of novel substrate based inhibitors of HIV-1 protease
  作者：S. Rajesh、Ei'ichi Ami、Tomoya Kotake、Tooru Kimura、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/s0960-894x(02)00781-3

  日期：2002.12

  Z- and Fmoc-L-tetrahydrofuranylglycines have been obtained from L-vinylglycine through dipolar cycloaddition reaction, and its Fmoc derivative has been applied in the synthesis of modified S9 and S10 substrates of HIV-1 protease. These compounds mostly acted as strong inhibitors, rather than substrates, of the protease, probably due to the favourable interactions of the tetrahydrofuranylglycine moiety

  通过偶极环加成反应从L-乙烯基甘氨酸获得Z-和Fmoc-L-四氢呋喃基甘氨酸，并且其Fmoc衍生物已被用于合成HIV-1蛋白酶的修饰的S9和S10底物。这些化合物主要充当蛋白酶的强抑制剂，而不是底物，这可能是由于四氢呋喃基甘氨酸部分在S（2）位点的良好相互作用。
• Peptide Weinreb amide derivatives as thioester precursors for native chemical ligation
  作者：Chang Rao、Chuan-Fa Liu

  DOI：10.1039/c7ob00103g

  日期：——

  Peptide Weinreb amide derivatives with an N-substituted mercaptoethyl group are designed as thioester precursors for native chemical ligation. We show that these amides undergo rapid ligation with a cysteinyl peptide under normal NCL conditions to form various Xaa–Cys peptide bonds, including the difficult Val–Cys junction. Facile synthesis of the Weinreb amide linkers allows easy access to this new

  具有N-取代的巯基乙基的肽Weinreb酰胺衍生物被设计为用于天然化学连接的硫酯前体。我们表明，这些酰胺在正常NCL条件下与半胱氨酰肽快速连接，形成各种Xaa-Cys肽键，包括困难的Val-Cys连接。通过标准的Fmoc固相合成，Weinreb酰胺连接基的简便合成可以轻松获得这种新型的肽硫酯前体。
• Hierarchical supramolecular hydrogels: self-assembly by peptides and photo-controlled release <i>via</i> host–guest interaction
  作者：Chih-Wei Chu、Bart Jan Ravoo

  DOI：10.1039/c7cc07859e

  日期：——

  A hierarchical supramolecular hydrogel was self-assembled from a Fmoc-RGDS tetrapeptide and showed photo-controlled release directed by host–guest interaction. Multiple payloads, including vesicles, were successively released from a single peptide hydrogel.

  分层的超分子水凝胶是由Fmoc-RGDS四肽自组装而成的，显示出受主与客体相互作用的光控释放。从单个肽水凝胶中连续释放出多种有效载荷，包括囊泡。
• Novel compounds and therapeutic uses thereof
  申请人：TORRENT PHARMACEUTICALS LTD.

  公开号：US20040106802A1

  公开（公告）日：2004-06-03

  The invention discloses a novel series of compound represented by general formula (I), 1 its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetes, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals of mammals. The invention also discloses pharmaceutically acceptable composition comprising these compounds, method for preparation of the compounds as defined above and method of treating mamnnals including human beings by administering an effective amount of said compounds to a subject in need thereof. The invention further discloses use of these compounds in the manufacture of a medicament useful for treatment of different disease conditions as stated above.

  该发明揭示了一种由通式(I)表示的新型化合物系列，其衍生物、类似物、互变异构体、立体异构体、多型体、药用可接受盐、溶剂合物，其中X、n、k、z、R1、R2、R3、R4、R5和R6如规范中定义的那样，在(i)正常化糖尿病患者的升高血糖水平，(ii)治疗与葡萄糖不耐受有关的疾病，以及(iii)清除哺乳动物体内自由基方面具有用处。该发明还揭示了包括这些化合物的药用可接受组合物，所述化合物的制备方法如上所述，并通过向需要的受试者施用有效量的该化合物来治疗包括人类在内的哺乳动物的方法。该发明进一步揭示了这些化合物在制造用于治疗上述不同疾病状况的药物中的应用。